In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.
CpG
GM-CSF
dendritic cells
melanoma
sentinel lymph node
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
09
2019
revised:
25
10
2019
accepted:
26
10
2019
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
epublish
Résumé
Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.
Identifiants
pubmed: 32002303
doi: 10.1080/2162402X.2019.1708066
pii: 1708066
pmc: PMC6959435
doi:
Substances chimiques
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1708066Informations de copyright
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Mol Med Rep. 2013 Oct;8(4):1149-54
pubmed: 23982226
Ann Rheum Dis. 2016 Sep;75(9):1728-34
pubmed: 26493814
Blood. 2011 Sep 1;118(9):2502-10
pubmed: 21750314
Immunity. 2016 Sep 20;45(3):626-640
pubmed: 27637148
J Immunol. 2017 Feb 1;198(3):1156-1163
pubmed: 28003378
Clin Cancer Res. 2017 Oct 1;23(19):5679-5686
pubmed: 28972083
Eur J Immunol. 2013 Jul;43(7):1693-7
pubmed: 23828296
J Clin Oncol. 2010 Sep 10;28(26):4038-44
pubmed: 20644089
Clin Cancer Res. 2007 May 15;13(10):2961-9
pubmed: 17504997
Sci Immunol. 2018 Jan 26;3(19):
pubmed: 29374079
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
Front Oncol. 2018 Aug 21;8:322
pubmed: 30186768
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
Cancer Immunol Immunother. 2016 Sep;65(9):1015-34
pubmed: 27372293
PLoS One. 2012;7(9):e45171
pubmed: 23028824
J Immunol Res. 2017;2017:9212134
pubmed: 29318162
Clin Cancer Res. 2011 Apr 1;17(7):1765-75
pubmed: 21233400
Int J Cancer. 2019 Aug 15;145(4):974-978
pubmed: 30694555
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Cancer Res. 2004 Nov 15;64(22):8456-60
pubmed: 15548718
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
pubmed: 9843981
J Clin Invest. 2013 Oct;123(10):4464-78
pubmed: 24091328
Am J Pathol. 2005 Nov;167(5):1301-7
pubmed: 16251414
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Cancer Immunol Res. 2015 May;3(5):495-505
pubmed: 25633713
Ann Oncol. 2007 Feb;18(2):226-32
pubmed: 17116643
Lancet Oncol. 2016 Jun;17(6):757-767
pubmed: 27161539
J Immunother Cancer. 2014 May 13;2:11
pubmed: 24971166
Cancer Immunol Res. 2015 Sep;3(9):986-91
pubmed: 25943535
Cell Immunol. 2015 Apr;294(2):87-94
pubmed: 25708485
J Immunol. 2006 Jun 15;176(12):7232-42
pubmed: 16751366